| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V74763 | Catumaxomab | 509077-98-9 | Catumaxomab is a trifunctional IgG2 antibody consisting of mouse and rat heavy and light chains that binds to human EpCAM and human CD3 receptors. |
|
V51153 | Cevostamab (BFCR-4350A; RG-6160; RO-7187797) | 2249888-53-5 | Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized, IgG1-based BsAb that can inhibit the membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells and CD3 on T cells. |
|
V74765 | Dafsolimab (SPV-T3a) | 2367001-71-4 | Dafsolimab (SPV-T3a) is an IgG2a mouse monoclonal antibody (mAb) (anti-CD3). |
|
V74762 | Epcoritamab (GEN3013) | 2134641-34-0 | Epcoritamab (GEN3013; Epkinly) is a bispecific IgG1 antibody that redirects T cells to CD3×CD20+ tumor cells. |
|
V51171 | Flotetuzumab (MGD-006; S-80880) | 1664355-28-5 | Flotetuzumab (MGD006; S80880) is a dual-potential CD123/CD3 dual-affinity re-inhibitor (DART) superior. |
|
V51162 | Foralumab (NI-0401) | 946415-64-1 | Foralumab (NI-0401) is a trauma-effective, humanized monoclonal antibody (mAb) that can inhibit CD3. |
|
V51155 | Gresonitamab (AMG-910) | 2413817-97-5 | Gresonitamab (AMG 910) is a half-life extending (HLE) bipotential T cell engager (BiTE) precursor that can inhibit CD3-positive T cells and tumor cells expressing CLDN18.2. |
|
V51154 | Muromonab | 140608-64-6 | Muromonab is a monoclonal antibody (mAb) that can inhibit CD3 capture. |
|
V51164 | Obrindatamab (MGD-009) | 2069959-72-2 | Obrindatamab is a humanized anti-B7-H3/CD3 bipotent. |
|
V51161 | Otelixizumab | 881191-44-2 | Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody (mAb) utilized in study/research of type 1 diabetes. |
|
V51156 | Pacanalotamab (AMG-420; BI-836909) | 2251756-52-0 | Pacanalotamab (AMG 420; BI-836909) is a dual-channel T cell reagent (BiTE) that activates BCMA and CD3ɛ. |
|
V51172 | Pasotuxizumab (BAY-2010112) | 1442657-12-6 | Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bipotent T cell engager (BiTE). |
|
V51170 | Pavurutamab (AMG-701) | 2250292-39-6 | Pavurutamab (AMG-701) is an anti-CD3 and anti-B mature cell active (BCMA) dual-channel T-adhesive molecule. |
|
V51168 | Solitomab (AMG-110) | 1005198-65-1 | Solitomab (AMG 110) is a bipotential anti-CD3 and anti-epithelial cell marker molecule (EpCAM) antibody. |
|
V51151 | Talquetamab (JNJ-64407564) | 2226212-40-2 | Talquetamab (JNJ-64407564; Talvey) is a humanized bipotential binding antibody that binds to GPRC5D (G protein-coupled receptor family C5 group member D) and CD3 to induce T cell-mediated T cell recruitment and activation. |
|
V51150 | Teclistamab | 2119595-80-9 | Teclistamab is a humanized BCMA and CD3 dual probe that recognizes BCMA on target cells and CD3 on T cells, inducing T cell-mediated cytotoxic effect, leading to activation of T cells and subsequent target cell mitochondria. |
|
V51152 | Teplizumab (MGA-031; PRV-031) | 876387-05-2 | Teplizumab (MGA-031) is an Fc receptor-type, non-binding type monoclonal antibody (mAb) against human CD3. |
|
V51160 | Tepoditamab (MCLA-117) | 2044679-53-8 | Tepoditamab (MCLA-117) is a dual lung cancer monoclonal antibody (mAb) that binds to CLEC12A on myeloid cells and CD3 on toxic T cells. |
|
V51165 | Tidutamab (XmAb-18087) | 2148354-90-7 | Tidutamab (XmAb-18087) is a humanized and affinity-optimized dual transport binding antibody (bsAb) that can inhibit the SSTR2 domain and the T cell binding domain (CD3). |
|
V51167 | Ubamatamab (REGN-4018) | 2305629-50-7 | Ubamatamab (REGN4018) is a human bispecific antibody targeting mucin 16 (MUC16) and CD3. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
